Chemogenomic profiling predicts antifungal synergies

Chemotherapies, HIV infections, and treatments to block organ transplant rejection are creating a population of immunocompromised individuals at serious risk of systemic fungal infections. Since single‐agent therapies are susceptible to failure due to either inherent or acquired resistance, alternative therapeutic approaches such as multi‐agent therapies are needed. We have developed a bioinformatics‐driven approach that efficiently predicts compound synergy for such combinatorial therapies. The approach uses chemogenomic profiles in order to identify compound profiles that have a statistically significant degree of similarity to a fluconazole profile. The compounds identified were then experimentally verified to be synergistic with fluconazole and with each other, in both Saccharomyces cerevisiae and the fungal pathogen Candida albicans. Our method is therefore capable of accurately predicting compound synergy to aid the development of combinatorial antifungal therapies.

[1]  R. Homayouni,et al.  The Transcription Factor Mrr1p Controls Expression of the MDR1 Efflux Pump and Mediates Multidrug Resistance in Candida albicans , 2007, PLoS pathogens.

[2]  S. Loewe.  The problem of synergism and antagonism of combined drugs. , 1953, Arzneimittel-Forschung.

[3]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[4]  Mark Gerstein,et al.  Biochemical and genetic analysis of the yeast proteome with a movable ORF collection. , 2005, Genes & development.

[5]  J. Lehár,et al.  High-order combination effects and biological robustness , 2008, Molecular systems biology.

[6]  Hervé Hogues,et al.  Transcriptional Rewiring of Fungal Galactose-Metabolism Circuitry , 2007, Current Biology.

[7]  Sean R. Collins,et al.  Exploration of the Function and Organization of the Yeast Early Secretory Pathway through an Epistatic Miniarray Profile , 2005, Cell.

[8]  Bootstrap Methods and Permutation Tests * , 2022 .

[9]  Sean R. Collins,et al.  A comprehensive strategy enabling high-resolution functional analysis of the yeast genome , 2008, Nature Methods.

[10]  P. Sorger,et al.  Systems biology and combination therapy in the quest for clinical efficacy , 2006, Nature chemical biology.

[11]  R. Homayouni,et al.  A Gain-of-Function Mutation in the Transcription Factor Upc2p Causes Upregulation of Ergosterol Biosynthesis Genes and Increased Fluconazole Resistance in a Clinical Candida albicans Isolate , 2008, Eukaryotic Cell.

[12]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[13]  S. Clissold,et al.  Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. , 1990, Drugs.

[14]  Inmar E. Givoni,et al.  Exploring the Mode-of-Action of Bioactive Compounds by Chemical-Genetic Profiling in Yeast , 2006, Cell.

[15]  C. Sander,et al.  Models from experiments: combinatorial drug perturbations of cancer cells , 2008, Molecular systems biology.

[16]  Gavin Sherlock,et al.  Global analysis of gene function in yeast by quantitative phenotypic profiling , 2006, Molecular systems biology.

[17]  Grant W. Brown,et al.  Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways , 2004, Nature Biotechnology.

[18]  David Y. Thomas,et al.  Population genomics of drug resistance in Candida albicans , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Jian Wang,et al.  High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infections , 2007, Proceedings of the National Academy of Sciences.

[20]  Chen Gao,et al.  On the Mechanism of Constitutive Pdr1 Activator-mediated PDR5 Transcription in Saccharomyces cerevisiae , 2004, Journal of Biological Chemistry.

[21]  C. I. Bliss.  THE TOXICITY OF POISONS APPLIED JOINTLY1 , 1939 .

[22]  Ronald W. Davis,et al.  Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. , 1999, Science.

[23]  F. Barchiesi,et al.  In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. , 1998, The Journal of antimicrobial chemotherapy.

[24]  Robert P. St.Onge,et al.  The Chemical Genomic Portrait of Yeast: Uncovering a Phenotype for All Genes , 2008, Science.

[25]  T. C. White,et al.  Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance , 1998, Clinical Microbiology Reviews.

[26]  Corey Nislow,et al.  Combination chemical genetics. , 2008, Nature chemical biology.

[27]  Paul A Clemons,et al.  Chemical genomic profiling of biological networks using graph theory and combinations of small molecule perturbations. , 2003, Journal of the American Chemical Society.

[28]  Thomas J Walsh,et al.  Antifungal chemotherapy: advances and perspectives. , 2002, Swiss medical weekly.

[29]  Chao Zhang,et al.  An integrated platform of genomic assays reveals small-molecule bioactivities. , 2008, Nature chemical biology.

[30]  C. Heitman.  Unique Applications of Novel Antifungal Drug Combinations , 2007 .

[31]  S. Pongor,et al.  Multiple weak hits confuse complex systems: a transcriptional regulatory network as an example. , 2004, Physical review. E, Statistical, nonlinear, and soft matter physics.

[32]  H. Mori,et al.  Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection , 2006, Molecular systems biology.

[33]  J. Lehár,et al.  Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.

[34]  Hao Li,et al.  The Evolution of Combinatorial Gene Regulation in Fungi , 2008, PLoS biology.

[35]  F. Sams-Dodd.  Target-based drug discovery: is something wrong? , 2005, Drug discovery today.

[36]  David Y. Thomas,et al.  Drag&Drop cloning in yeast. , 2005, Gene.

[37]  Ping Wang,et al.  The cyclophilins , 2005, Genome Biology.

[38]  Robert P. St.Onge,et al.  Genome-Wide Requirements for Resistance to Functionally Distinct DNA-Damaging Agents , 2005, PLoS genetics.

[39]  B. Stockwell,et al.  Multicomponent therapeutics for networked systems , 2005, Nature Reviews Drug Discovery.

[40]  André Nantel,et al.  Transcription factor substitution during the evolution of fungal ribosome regulation. , 2008, Molecular cell.

[41]  Navin Pokala,et al.  High Rates of Actin Filament Turnover in Budding Yeast and Roles for Actin in Establishment and Maintenance of Cell Polarity Revealed Using the Actin Inhibitor Latrunculin-A , 1997, The Journal of cell biology.

[42]  L. Johnson,et al.  Protein Kinase Inhibitors: Insights into Drug Design from Structure , 2004, Science.

[43]  J. Lehár,et al.  Systematic discovery of multicomponent therapeutics , 2003, Proceedings of the National Academy of Sciences of the United States of America.